Medicine/7. Clinical medicine
Parakhonsky
A.P.
Kuban medical
institute, Medical center "Health", Krasnodar, Russia
The
nature of the interaction of cells in inflammatory response
Specific
arterial sites, such as branches, bifurcations, and curvatures, cause characteristic
alterations in the flow of blood, including decreased shear stress and increased
turbulence. At these sites, specific molecules form on the endothelium that is
responsible for the adherence, migration, and accumulation of monocytes and T-
cells. Such
adhesion molecules, which act as receptors for glycoconjugates and integrins
present on monocytes and T cells, include several selectins, intercellular
adhesion molecules, and vascular-cell adhesion molecules. Molecules associated with the migration of leukocytes across the
endothelium, such as platelet – endothelial-cell adhesion molecules, act in
conjunction with chemoattractant molecules generated by the endothelium, smooth
muscle, and monocytes - such as monocyte chemotactic protein 1, osteopontin,
and modified LDL - to attract monocytes and T cells into the artery. The nature
of the flow - that is, whether shear stress or turbulence is high or low -
appears to be important in determining whether lesions occur at these vascular
sites. Changes in
flow alter the expression of genes that have elements in their promoter regions
that respond to shear stress. For example, the genes for intercellular adhesion
molecule 1, platelet-derived growth factor B chain, and tissue factor in
endothelial cells have these elements, and their expression is increased by
reduced shear stress. Thus, alterations in blood flow appear to be critical in
determining which arterial sites are prone to have lesions. Rolling and
adherence of monocytes and T cells occur at these sites as a result of the
up-regulation of adhesion molecules on both the endothelium and the leukocytes.
Chemokines
may be responsible for the chemotaxis and accumulation of macrophages in fatty
streaks. Activation
of monocytes and T cells leads to up-regulation of receptors on their surfaces,
such as the mucin-like molecules that bind selectins, integrins that bind
adhesion molecules of the immunoglobulin superfamily, and receptors that bind
chemoattractant molecules. These ligand-receptor
interactions further activate mononuclear cells, induce cell proliferation, and
help define and localize the inflammatory response at the sites of lesions. Thus, adherence of monocytes and
T cells may occur after an increase in one or more of the adhesion molecules,
which may act in concert with chemotactic molecules such as monocyte
chemotactic protein 1, interleukin-8, or modified LDL. Comparison
of the relative roles of these molecules in inflammation in the arteries and
the microvasculature may provide clues to the relative feasibility of modifying
the inflammatory process at these sites, and thus of modifying atherosclerosis.
A
recently discovered class of molecules, the disintegrins, sometimes called metalloproteinase-like,
disintegrin-like, cysteine-rich proteins (MDCs), has been identified in
endothelium, smooth muscle, and macrophages. These transmembrane proteins,
which appear to be involved in cell-cell interactions, contain a
metalloproteinase sequence in their extracellular segment that permits them to
activate molecules such as tumor necrosis factor α. They are not found in
normal arteries, but one of them, MDC15, is present in lesions of
atherosclerosis. Adhesion molecules such as L-selectin can be cleaved from the
surface of leukocytes by a metalloproteinase (L-selectin sheddase), which
suggests that in situations of chronic inflammation it may be possible to
measure the “shed” molecules, such as the different adhesion molecules, in
plasma, as markers of a sustained inflammatory response. Disintegrins may participate in
these shedding processes. If shedding occurs, it may be detectable in different
types of inflammatory responses. Increased plasma concentrations of shed
molecules might then be used to identify patients at risk for atherosclerosis
or other inflammatory diseases.
The ubiquitous monocyte, the precursor of
macrophages in all tissues, is present in every phase of atherogenesis.
Monocyte-derived macrophages are scavenging and antigen-presenting cells, and
they secrete cytokines, chemokines, growth-regulating molecules, and
metalloproteinases and other hydrolytic enzymes. The
continuing entry, survival, and replication of mononuclear cells in lesions
depend in part on factors such as macrophage colony-stimulating factor and
granulocyte-macrophage colony-stimulating factor for monocytes and interleukin-2
for lymphocytes. Continued
exposure to macrophage colony-stimulating factor permits macrophages to survive
in vitro and possibly to multiply within the lesions. In
contrast, inflammatory cytokines such as interferon-γ
activate macrophages and under certain circumstances induce them to undergo programmed
cell death (apoptosis). If this occurs in vivo, macrophages may become involved
in the necrotic cores characteristic of advanced, complicated lesions. Initially, the only cells
thought to proliferate during expansion of atherosclerotic lesions were
smooth-muscle cells. However, replication of monocyte-derived
macrophages and T-cells is probably of equal importance. The ability of macrophages to
produce cytokines (such as tumor necrosis factor α, interleukin-1, and
transforming growth factor β), proteolytic enzymes (particularly
metalloproteinases), and growth factors (such as platelet-derived growth factor
and insulin-like growth factor I) may be critical in the role of these cells in
the damage and repair that ensue as the lesions progress.
Activated macrophages express class II
histocompatibility antigens such as HLA-DR that allow them to present antigens
to T lymphocytes. Thus, it is not surprising that cell-mediated immune
responses may be involved in atherogenesis, since both CD4 and CD8 T cells are
present in the lesions at all stages of the process. T cells are activated when
they bind antigen processed and presented by macrophages. T-cell activation results in the secretion of cytokines, including
interferon-γ and tumor necrosis factor α and β, that
amplify the inflammatory response. Smooth-muscle cells from the lesions also
have class II HLA molecules on their surfaces, presumably induced by
interferon-γ, and can also present antigens to T cells. One possible antigen may be
oxidized LDL, which can be produced by macrophages. Heat-shock protein 60 may also
contribute to autoimmunity. This and other heat-shock proteins perform several
functions, including the assembly, intracellular transport, and breakdown of
proteins and the prevention of protein denaturation. These
proteins may be elevated on endothelial cells and participate in immune
responses. An immunoregulatory molecule, CD40 ligand, can be expressed by
macrophages, T-cells, endothelium, and smooth muscle in atherosclerotic lesions
in vivo, and its receptor, CD40, is expressed on the same cells. Both are up-regulated in lesions
of atherosclerosis, providing further evidence of immune activation in the
lesions. Furthermore, CD40 ligand induces the release of interleukin-1β by
vascular cells, potentially enhancing the inflammatory response. Inhibition of CD40 with blocking antibodies reduces lesion formation in
apolipoprotein E-deficient mice.
Platelet
adhesion and mural thrombosis are ubiquitous in the initiation and generation
of the lesions of atherosclerosis in animals and humans. Platelets can adhere to
dysfunctional endothelium, exposed collagen, and macrophages. When activated,
platelets release their granules, which contain cytokines and growth factors
that, together with thrombin, may contribute to the migration and proliferation
of smooth-muscle cells and monocytes. Activation of platelets
leads to the formation of free arachidonic acid, which can be transformed into
prostaglandins such as thromboxane A2, one of the most potent vasoconstricting
and platelet-aggregating substances known, or into leukotrienes, which can
amplify the inflammatory response.
Plaque
rupture and thrombosis are notable complications of advanced lesions that lead
to unstable coronary syndromes or myocardial infarction. Platelets are important in
maintaining vascular integrity in the absence of injury and protecting against
spontaneous hemorrhage. Activated platelets can accumulate on the walls of
arteries and recruit additional platelets into an expanding thrombus. An important
component of the platelets is the glycoprotein IIb/IIIa receptor, which belongs
to the integrin superfamily of adhesion-molecule receptors and appears on the
surface of platelets during platelet activation and thrombus formation. These receptors serve an important hemostatic function, and antagonists
to them prevent thrombus formation in patients who have had a myocardial
infarction.
Monocytes
play important roles in the initiation, progression and complications of
atherosclerosis. Their recruitment to the artery wall, their differentiation to
macrophages, and their phenotypes can be modulated by factors present within
the microenvironment of the artery wall, including oxidized lipids, TLR
ligands, hematopoietic growth factors, cytokines, and chemokines. Within
atherosclerotic plaques, the dynamic modulation of macrophage phenotypes
impacts atherosclerosis progression by modulating ongoing inflammatory
responses within the vessel wall, by regulating apoptotic cell clearance within
the developing plaque, and by egress mechanisms. Thus, the dynamic roles that
macrophages play in early and advanced atherosclerotic plaques make macrophage
phenotype modulation an attractive therapeutic targets for the prevention and
treatment of cardiovascular disease.